|By Marketwired .||
|December 1, 2016 09:00 AM EST|
ATLANTA, GA -- (Marketwired) -- 12/01/16 -- In recognition of World AIDS Day on December 1, GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company specializing in developing human vaccines, encourages everyone to get tested for HIV, the virus that causes AIDS.
Around the world, about 35 million people are living with HIV. In the United States, about 50,000 people become infected with HIV every year. World AIDS Day is a global initiative to raise awareness, fight prejudice, and improve education about HIV and AIDS.
In the United States, about 1 in 5 people who have HIV don't know they are infected, and the only way to know one's infection status is to be tested. In fact, the U.S. Office of Disease Prevention and Health Promotion recommends that everyone aged 15 to 65 should be tested at least once. To find an HIV testing location near you, use the online locator at https://locator.aids.gov.
Getting tested is important for both the individual and for world health. For the individual, early detection will allow sooner intervention with anti-retroviral medication and prevention of the infection progressing to AIDS, thus allowing a near-normal life. But just as importantly, drug treatment means the infected individual will be much less likely to spread HIV to others.
GeoVax is committed to an AIDS-free generation through vaccine development. Our HIV vaccine candidate is currently progressing through human clinical trials conducted by the HIV Vaccine Trials Network (HVTN) with support from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). To learn more about our work to fight HIV, visit www.geovax.com.
GeoVax Labs, Inc., is a clinical-stage biotechnology company developing human vaccines against infectious diseases using its Modified Vaccinia Ankara-Virus Like Particle (MVA-VLP) vaccine platform. The Company's development programs are focused on vaccines against HIV, Zika Virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa) and malaria. GeoVax also is evaluating the use of its MVA-VLP platform in cancer immunotherapy, and for therapeutic use in chronic Hepatitis B infections. GeoVax's vaccine platform supports in vivo production of non-infectious VLPs from the cells of the very person receiving the vaccine, mimicking a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. For more information, visit www.geovax.com.
Robert T. McNally, Ph.D.
GeoVax Labs, Inc.
Dec. 7, 2016 09:15 AM EST Reads: 1,048
Dec. 7, 2016 09:15 AM EST Reads: 4,597
Dec. 7, 2016 09:15 AM EST Reads: 7,234
Dec. 7, 2016 08:30 AM EST Reads: 1,856
Dec. 7, 2016 08:15 AM EST Reads: 480
Dec. 7, 2016 08:00 AM EST Reads: 423
Dec. 7, 2016 07:45 AM EST Reads: 812
Dec. 7, 2016 07:30 AM EST Reads: 820
Dec. 7, 2016 06:45 AM EST Reads: 1,997
Dec. 7, 2016 06:30 AM EST Reads: 1,811
Dec. 7, 2016 06:15 AM EST Reads: 5,331
Dec. 7, 2016 05:15 AM EST Reads: 1,062
Dec. 7, 2016 04:00 AM EST Reads: 870
Internet of @ThingsExpo has announced today that Chris Matthieu has been named tech chair of Internet of @ThingsExpo 2017 New York The 7th Internet of @ThingsExpo will take place on June 6-8, 2017, at the Javits Center in New York City, New York. Chris Matthieu is the co-founder and CTO of Octoblu, a revolutionary real-time IoT platform recently acquired by Citrix. Octoblu connects things, systems, people and clouds to a global mesh network allowing users to automate and control design flo...
Dec. 7, 2016 02:00 AM EST Reads: 645
In addition to all the benefits, IoT is also bringing new kind of customer experience challenges - cars that unlock themselves, thermostats turning houses into saunas and baby video monitors broadcasting over the internet. This list can only increase because while IoT services should be intuitive and simple to use, the delivery ecosystem is a myriad of potential problems as IoT explodes complexity. So finding a performance issue is like finding the proverbial needle in the haystack.
Dec. 7, 2016 01:45 AM EST Reads: 6,167